Guest post: A European perspective on the CAD
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Guest post: A European perspective on the CAD

Bass_Kyle-100

We have been following the reporting of Inter Partes Review (IPR) filings by the Coalition for Affordable Drugs against pharmaceutical patents at the Patent Trial and Appeal Board, writes Nick Richards of Bristows in London



Richards Nick Bristows
Nick Richards

As has been well publicised, critics of fund manager Kyle Bass and nXn owner Erich Spangenberg, who formed the Coalition, object to the use of IPRs to the extent they are initiated with the aim of driving down the share prices of patent holders so as to make a financial return from short positions on those stocks. We’ve been particularly intrigued by the debate concerning the legality and morality of the practice in the US.

Would the technique, if applied in the UK, be legal?

In short, no. If the strategy were to be employed in relation to UK listed stock, it would fall foul of the UK market abuse legislation, specifically the prohibitions on insider dealing. Knowledge of an impending patent claim intended to depress the stock price of a company once announced would be sufficiently precise and significant to satisfy the definition of inside information.

What’s the legal landscape?

The market abuse regime across the European Union derives from the European Commission’s Market Abuse Directive (2003/6/EC) (MAD). In the UK, the relevant legislation has been implemented in the Financial Services and Markets Act 2000.

The UK legislation provides that the civil offence of insider dealing occurs where an “insider” deals or attempts to deal in a “qualifying or related investment” on the basis of “inside information” relating to the investment in question.

If we unpack those definitions in turn:

(i)         a “qualifying or related investment” is any financial instrument (including stock and any instrument which achieves a short position in relation to such stock) admitted to a prescribed market (for example, the London Stock Exchange);

(ii)        “inside information” is information of a precise nature which is not generally available, relates, directly or indirectly, to one or more issuers of the qualifying or related investment; and would, if generally available, be likely to have a significant effect on the price of the qualifying investments or on the price of related investments

(iii)       an “insider” is a person who has inside information:

(a) as a result of his membership of the administrative, management or supervisory bodies of an issuer of qualifying investments; (b) as a result of his holding in the capital of an issuer of qualifying investments; (c) as a result of having access to the information through the exercise of his employment, profession or duties; (d) as a result of his criminal activities; or (e) which he has obtained by other means and which he knows, or could reasonably be expected to know, is inside information.

Does this include third parties?

"The mere fact of knowledge that a UK listed company’s patent is challengeable ... would make the holder of such knowledge an insider for the purposes of the UK market abuse regime."

Although inside information is commonly information in the hands of a person who is an employee or adviser of a listed company, the definition of inside information in the UK legislation is sufficiently wide to encompass any information in the hands of a third party, even though that third party has not acquired the knowledge through privileged access to the listed company of the kind just described: anyone who has such inside information is an “insider”, because limb (e) extends the definition of an insider to any person who has inside information which he has obtained by other means and which he knows, or could reasonably be expected to know, is inside information.

The mere fact of knowledge that a UK listed company’s patent is challengeable, even if that knowledge were to be gained by lawful and diligent research, would make the holder of such knowledge an insider for the purposes of the UK market abuse regime.

What is the territorial scope of the UK legislation?

Kyle Bass
Kyle Bass, CAD

The civil market abuse regime applies to anyone (corporate or individual) who abuses a prescribed market. It supplements (and to some extent cuts across) the criminal regime for insider dealing in the UK legislation. The territorial scope is such that the market abuse regime applies to conduct with no jurisdictional connection with the UK other than the fact that it relates to an investment traded in the country. It’s become a cliché to observe that the US and UK are two nations divided by a common language. Seemingly in our common law jurisdictions, we’re also divided in the application of our respective securities law to the patent trolls’ move on the stock exchange.

What about Germany?

We have spoken to contacts at Hengeler Mueller to get a German perspective. In civil law Germany, the MAD has been implemented in the Wertpapierhandelsgesetz (Securities Trading Act). Under the German legislation, it is illegal for anybody to trade in “insider securities” using “inside information”.

While the wording and structure of these definitions differ slightly in the German legislation from their UK equivalents outlined above, there are no material distinctions that go to differentiate the German insider dealing analysis from that of the UK. It is likely that under German law, both the knowledge that a German listed company’s patent can be challenged successfully and the knowledge that it will actually be challenged would constitute inside information.

Trading on the basis of such inside information would be subject to German criminal sanctions.

Nick Richards is a senior associate in the corporate team at Bristows in London

more from across site and ros bottom lb

More from across our site

Ireland joining the UPC would offer plenty of opportunities to local attorneys but there are fears that upcoming referendum could get ‘lost in the noise’
Attorneys at four firms reveal the business opportunities that stem from patent licensing agreements in the life sciences sector
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Counsel at four firms explain their lateral hiring policies and how they retain existing lawyers
Lori Gordon, who has joined from Perkins Coie, says she hopes to turn Goodwin into a 'premier' destination for PTAB work
The LMG Life Sciences Awards is thrilled to present the shortlist for the 2024 EMEA Awards.
Partners at LeanWill Law Firm, a newly launched domestic firm in China, discuss IP opportunities and which clients they plan to target
Each week Managing IP speaks to a different IP lawyer about their life and career
A survey of more than 25,000 in-house lawyers reveals that embracing technology could help law firms win new business
John Mulgrew, vice president of IP at Lenovo, says the EU's proposed regulation will readdress imbalances in the bargaining power of SEP owners and implementers
Gift this article